Portland's strategy on track
Wednesday, 25 June, 2008
Portland Orthopedics' (ASX: PLD) strategy of expanding the distribution of its hip replacement products in the US and Australian markets seems to be working, investors were told yesterday, but the company is yet to see profitability.
By the end of June Portland's artifical hips will have been implanted in 480 US patients and 100 Australian patients within the last 12 months, according to company predictions.
Portland has also lodged a non-renounceable rights issue, offering existing shareholders a one-for-one deal to raise up to $4 million.
The company said it had made major reductions in its operating costs, and is seeing a double-figure revenue increase in 2008 compared to the first half of the financial year.
Portland's next immediate goal is to achieve profitability and positive cash flow.
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
Osteoarthritis study uncovers new genetic links, drug targets
The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...
How brain cells are affected by Tourette syndrome
US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...
